Real-world Experience. Thank you to everyone who shared their real-world experience at #EuroPCR 2025 during our symposium about #LithiX Hertz Contact Intravascular #Lithotripsy today. It was amazing to hear the panel discuss the versatility and effectiveness of this novel

That’s a wrap on #EuroPCR 2025! Elixir Medical is proud to have contributed to this year’s conversations around advancing PCI technologies. From the 3-year BIOADAPTOR-RCT data to LithiX technology and calcium fragmentation, we are honored to share our work with the global

That’s a wrap on #EuroPCR 2025! Elixir Medical is proud to have contributed to this year’s conversations around advancing PCI technologies. From the 3-year BIOADAPTOR-RCT data to LithiX technology and calcium fragmentation, we are honored to share our work with the global

ICYMI: Elixir shared compelling 3-year outcomes from the BIOADAPTOR-RCT at #EuroPCR 2025, showcasing the long-term efficacy of the DynamX® Coronary Bioadaptor System. Presented by Shigeru Saito, as compared to stents, the data showed: – 63% reduction in target lesion failure

Please join us in celebrating Dr. Tak-Shun Chung and the interventional cardiology team at United Christian Hospital, named as finalists in this year’s DynamX XCase Competition. Their approach highlighted the real-world application of DynamX bioadaptor to preserve vessel motion

Congratulations to Omer Goktekin MD and the team at Memorial Bahcelievler Hospital for being selected as a finalist in the 2025 DynamX XCase Competition! Their featured case demonstrated thoughtful strategy and advanced imaging to restore vessel motion and function using the DynamX

We’re honored to be named one of Fast Company’s Most Innovative Companies— now, we’re excited to attend the 2025 Most Innovative Companies Summit & Gala in NYC. It’s more than an event — it’s a gathering of leaders, innovators, and visionaries from across industries, all focused

We’re honored to be named one of Fierce Medtech’s Fierce 15, recognizing the most promising private medtech companies making waves in innovation, impact, and real-world outcomes. At Elixir Medical, our mission to transform treatment for cardiovascular disease is only just

LithiX Hertz Contact Intravascular Lithotripsy (HC-IVL) enters clinical practice for the first time in the UK Prof. Mohaned Egred from Freeman hospital in the UK performed a successful LithiX intervention on a patient with severe coronary calcification in multiple lesions with

What an incredible night at the 2025 Fast Company Most Innovative Companies Summit & Gala last week! We’re feeling inspired and proud to have been part of such a powerful gathering of innovators and change-makers. We appreciated the opportunity to connect with fellow leaders,

2-year BIOADAPTOR RCT results published in “JACC: Cardiovascular Interventions.” “The BIOADAPTOR RCT has shown apparent flattening of the time-to-event curves and a widening of clinical benefit in favor of the bioadaptor group at 2-years.” Access the article:

Elixir Medical is proud to represent the San Francisco Bay Area on Fierce Medtech’s Fierce 15 list for 2025 — a hub of healthcare innovation that’s thriving more than ever. We're in amazing company this year alongside fellow Bay Area changemakers: • AvertoMedical • Capstan

For Polish physicians: Register today for the case-based discussion on how the treatment of Coronary Artery Disease with Bioadaptor could improve clinical outcomes We will be joined by the panel of experts Michal Hawranek will be sharing the biggest challenges in PCI today

For Polish physicians: Register today for the case-based discussion on the treatment of Coronary Artery Disease with #DynamXBioadaptor. We will be joined by the panel of experts Michal Hawranek will be sharing the biggest challenges in PCI today and how the novel mechanism of

Newly published data: BIOADAPTOR RCT shows TLF difference at 2 years is statistically significant in favor of DynamX® vs. DES. (1.8% vs. 5.5%; p=0.044) This trend continued out to 3-years, as presented by Dr. Shigeru Saito during the recently concluded #EuroPCR2025 congress.

DynamX® offers a new category of therapy for CAD. BIOADAPTOR RCT 2-year outcomes peer-reviewed publication by #JACC highlights the bioadaptor arm’s: ✅ Reduced adverse events ✅ Restoration of adaptive remodeling & pulsatility ✅ Reduced late lumen loss ✅ Behind-device plaque

Elixir Medical is co-hosting an upcoming webinar with CUHK Medical Centre: Advancing PCI with Bioadaptive Angioplasty Join us on Friday, July 11 at 7:50 p.m. HKT for expert insights into how bioadaptor technology may improve outcomes beyond the current standard of care. The

Tonight, Elixir Medical and CUHK Medical Centre co-host a webinar exploring how bioadaptive angioplasty can further advance PCI outcomes. We’re excited to hear from Drs. Gary Mak, Chan Yu Ho, Raymond Fung Chi Yan, and Chung Tak Shun as they share new clinical data and case

Thank you to everyone who joined our webinar with CUHK Medical Centre on Advancing PCI with Bioadaptive Angioplasty. We’re grateful to our speakers for sharing meaningful data and case experiences. If you missed the session, we’ll be sharing access to recordings and highlights

The DynamX bioadaptor offers physicians an alternative to DES that can restore coronary arteries to a more natural state after PCI with long-term benefits to the patient. But what does that look like in real life? “JACC: Case Reports” published an article where the authors